3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasm Metastasis
4
Lung Neoplasms
4
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Cholangiocarcinoma
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Tertiary Lymphoid Structures
1
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Nasopharyngeal Carcinoma
1
Microsatellite Instability
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
Hematologic Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Camurati-Engelmann Syndrome
1
Brain Neoplasms
1
Biliary Tract Neoplasms
1
Anatomic Stage II Breast Cancer AJCC v8
1
Interventions
pembrolizumab
36
Gemcitabine
29
Nivolumab
20
Cisplatin
19
atezolizumab
15
avelumab
14
Docetaxel
13
Carboplatin
10
enfortumab vedotin
9
durvalumab
9
Magnetic Resonance Spectroscopy
9
Ipilimumab
8
Paclitaxel
7
Pemetrexed
6
toripalimab
5
cabozantinib
5
Fluorodeoxyglucose F18
5
sacituzumab govitecan
4
cabazitaxel
4
Taxes
4
vinflunine
3
tremelimumab
3
pemigatinib
3
X-Rays
3
Standard of Care
3
Specimen Handling
3
Radiotherapy
3
Mitomycin
3
Immunotherapy
3
Immunoglobulin G
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Transitional Cell
×
bintrafusp alfa protein, human
×
Clear all
NCT04878250
2021-05-07
PEBBLE
Queen Mary University of London
Phase 2
Unknown
49 enrolled